A 24 Week Open-Label Extension to Study CENA713DUS44: A 24 Week Prospective Randomized Parallel-Group Double-Blind Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm2 vs. Rivastigmine Patch 5 cm2 on Activities of Daily Living and C
M
Martin Farlow, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
No Description Available
Description
No Description Available
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer
-
Age: - 100 Years
-
Gender: All
Updated on
18 Apr 2024.
Study ID: 1010002705 (1003-13)
